WuXi Biologics expands
Print Edition
WUXI Biologics, a Hong Kong-listed biopharmaceutical company, said yesterday that construction of a US$20 million integrated biologics conjugate R&D and manufacturing center has started in Wuxi in neighboring Jiangsu Province.
To be operational in 2019, the 6,000-square-meter facility will provide integrated solutions from concept to commercialization of biologics conjugates including Antibody-Drug Conjugates (ADCs) and other protein conjugates.
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic drug, which has been adopted for a number of innovative treatments for targeted tumor therapy.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
